Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 6/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | ALB | P02768 | 2/20 | 0.41 |
| ▸ | BLM | P54132 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16187026 | 1.00 | TK1 (0.44) | TK1ALDH1A1NPSR1LMNAALB | |
| Phosphoric Acid SCHEMBL7243142 | 0.95 | TYMP (0.43) | TK1LMNAALBBLMTSHR | |
| Phosphoric Acid SCHEMBL7240883 | 0.95 | TYMP (0.43) | TK1LMNAALBBLMTSHR | |
| SCHEMBL13253917 | 0.90 | ALDH1A1 (0.42) | TK1ALDH1A1NPSR1 | |
| SCHEMBL19387606 | 0.87 | TK1 (0.44) | TK1NPSR1LMNABLMADRA1A | |
| SCHEMBL29364921 | 0.86 | TK1 (0.45) | TK1ALDH1A1LMNAALBBLM | |
| SCHEMBL4809531 | 0.85 | TK1 (0.44) | TK1ALDH1A1LMNAALBBLM | |
| SCHEMBL8195055 | 0.85 | TK1 (0.38) | TK1NPSR1LMNABLMADRA1A | |
| SCHEMBL5849101 | 0.84 | TK1 (0.43) | TK1ALDH1A1LMNAALBBLM | |
| SCHEMBL7537552 | 0.84 | TK1 (0.43) | TK1ALDH1A1LMNAALBBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 670 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019195494-A1 | COMPOSITIONS AND METHODS FOR SYNTHESIS OF PHOSPHORYLATED MOLECULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-10-10 | — | — | WO | claimed |
| EP-1485395-A2 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | Biota, Inc. (US) | 2004-12-15 | — | — | EP | claimed |
| WO-2003072757-A9 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | BIOTA INC (US) | 2004-10-21 | — | — | WO | claimed |
| WO-2003072757-A2 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | BIOTA, INC. (US) | 2003-09-04 | — | — | WO | claimed |
| EP-0767842-B1 | METHODS OF SCREENING FOR NUCLEOSIDE ANALOGS THAT ARE INCORPORATED BY HIV REVERSE TRANSCRIPTASE AND CAUSE INCORRECT BASE PAIRING | UNIV WASHINGTON (US) | 2000-09-27 | — | — | EP | claimed |
| EP-1004675-A2 | Methods of screening for nucleoside analogs that are incorporated by HIV reverse transcriptase and cause incorrect base pairing | DARWIN MOLECULAR CORPORATION (US) | 2000-05-31 | — | — | EP | claimed |
| US-12584168-B2 | Sample preparation method | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2026-03-24 | — | — | US | disclosed |
| US-20260066042-A1 | METHODS AND SYSTEMS FOR HIGH-THROUGHPUT MOLECULAR ANALYSIS | OPENTRONS LABWORKS INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-12527846-B2 | Immunodominant proteins and fragments in multiple sclerosis | Universität Zürich (CH) | 2026-01-20 | — | — | US | disclosed |
| US-20250345413-A1 | SARS-COV-2 SUBUNIT VACCINE | Viravaxx AG (AT) | 2025-11-13 | — | — | US | disclosed |
| US-12466859-B2 | Desmoglein 2 (DSG2) binding proteins and uses therefor | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250332229-A1 | IMMUNODOMINANT PROTEINS AND FRAGMENTS IN MULTIPLE SCLEROSIS | Universität Zürich (CH) | 2025-10-30 | — | — | US | disclosed |
| EP-4640282-A2 | IMMUNODOMINANT PROTEINS AND FRAGMENTS IN MULTIPLE SCLEROSIS | Universität Zürich (CH) | 2025-10-29 | — | — | EP | disclosed |
| CN-86101696-A | Be used to induce in vivo compound technology with external generation phytokinin | — | 1986-12-24 | — | — | CN | disclosed |
| EP-0194393-A2 | Compounds for the induction of in vivo and in vitro production of cytokines | BAR ILAN UNIVERSITY (IL) | 1986-09-17 | — | — | EP | disclosed |
| US-4444776-A | ANTITUMOR, ANTIVIRAL | AGENCE NATIONALE DE VALORISATION DE LA RECHERCHE (A N V A R) (FR) | 1984-04-24 | — | — | US | disclosed |
| EP-0099133-A2 | Anti-cancer drugs comprising platinum complexes | YEDA RESEARCH AND DEVELOPMENT COMPANY, LTD. (IL) | 1984-01-25 | — | — | EP | disclosed |
| US-4377514-A | HOMOGENIZING, ACIDIFYING, DENATURING, AND CENTRIFUGING INTESTINAL LYMPH GLANDS; HORMONES | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 1983-03-22 | — | — | US | disclosed |
| US-4266060-A | ANTITUMOR ANTIVIRAL AGENTS FOR TREATMENT OF CANCER | AGENCE NATIONALE DE VAL ORISATION DE LA RECHERCHE (ANVAR) (FR) | 1981-05-05 | — | — | US | disclosed |
| US-4064007-A | ANTITUMOR AGENTS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 1977-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12584168-B2 | Sample preparation method | POLN, POLRMT, POLM | TK1 472/4885ALDH1A1 4810/4885NPSR1 2638/4885 |
| US-20260066042-A1 | METHODS AND SYSTEMS FOR HIGH-THROUGHPUT MOLECULAR ANALYSIS | POLRMT, POLL, SARS1 | TK1 1713/4885ALDH1A1 4286/4885NPSR1 2521/4885 |
| US-12527846-B2 | Immunodominant proteins and fragments in multiple sclerosis | MAG, GMFG, FUCA1 | TK1 3147/4885ALDH1A1 4407/4885NPSR1 2855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.